MedDataX Logo

The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases

NCT ID: NCT01180868

Last Updated: 2012-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the biodistribution of a new agent 1-L-(2 deoxy-2,-18fluoroarabinofuranosyl) cytosine non-invasively in healthy humans and to evaluate whether it can be used to image cancer, autoimmune disease, and inflammation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Diseases Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

imaging probe cancer inflammatory tissue inflammatory diseases

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with cancer

patients with hematological malignancies and solid tumors

No interventions assigned to this group

patients with autoimmune dosorders

patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.

No interventions assigned to this group

healthy subjects

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* greater than 18 years of age
* women of childbearing potential will undergo a pregnancy test free of charge
* patients with hematological malignancies, solid tumors or autoimmune disorders
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jonsson Comprehensive Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christiaan Schiepers, M.D. Ph.D

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCLA

Los Angeles, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DE-PS02-08ER08-01

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

CIRM No. RT1-01126-1

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

08-02-049

Identifier Type: -

Identifier Source: org_study_id